{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:20:41Z","timestamp":1787772041045,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"\n A\n BSTRACT<\/jats:sc>\n <\/jats:title>\n \n Background:<\/jats:title>\n Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with kidney complications. This study aims to investigate the effects of weekly subcutaneous semaglutide, a GLP-1 agonist, on kidney outcomes.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This retrospective cohort study was conducted in nephrology and endocrinology clinics at KFAFH from March 2022 to February 2023. The sample size was determined based on hospital records, and randomly selected patients who met the inclusion criteria were included. The inclusion criteria included adults with T2DM who were on weekly subcutaneous semaglutide for 6 months or longer. Patients with type 1 diabetes mellitus, pregnant or gestational diabetes patients, individuals who added other antidiabetic medications during the study period, and participants who refused to be involved were excluded from the study.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The study included participants aged between 42 and 85 years, with a mean age of 65.38 years, and the majority (58.7%) were males. There was a significant weight and BMI reduction observed in all patients, with\n P<\/jats:italic>\n values <0.001 for both. The average weight reduction was 2.97 kg (SD = 2.34, 95% CI 1.65\u20133.30), and the average Body (BMI) reduction was 1.16 (SD = 0.91, 95% CI 1.03\u20131.29). A vast majority of participants (98.5%) reported a weight loss of at least 1 kg, and 13.8% of participants experienced a change in BMI category from higher to lower. No patients reported an increase in the BMI category. There was a significant reduction in glycohemoglobin (HbA1c) measurements from 9.18 pretreatment to 8.13 posttreatment, with an average reduction of 1.05 units (SD = 1.84, 95% CI 0.79\u20131.31). The majority of participants (70.9%) reported a reduction in HbA1c of at least 0.1 unit. Although there was a slight decrease in estimated glomerular filtration rate (eGFR) values on average (1.35 units), the change was not statistically significant (\n P<\/jats:italic>\n = 0.059). More than half of the participants (51.5%) reported an increase in eGFR, 45.4% reported a decrease, and 3.1% reported no change. There was a statistically significant reduction in urinary albumin-to-creatinine ratio (UACR) values from a median of 5.97 pretreatment to a median of 5.60 post-treatment. The median decrease was 0.72 units, with one-third (33.3%) reporting an increase and two-thirds (66.7%) reporting a decrease in values. The correlation analysis revealed no significant association between the total quantity of semaglutide taken and the magnitude of changes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Our study on the impact of weekly semaglutide in adults with T2DM reveals positive effects on kidney outcomes, including weight loss, glycemic control and improved urine albumin creatine ratio, and a reduced risk of nephropathy. These findings highlight the potential of semaglutide as a safe and effective treatment option for improving renal health in individuals with T2DM.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1031_23","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:28:30Z","timestamp":1709638110000},"page":"532-536","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The impact of weekly semaglutide, a glucagon-like peptide-1 agonist, on kidney outcomes in adults with type 2 diabetes mellitus"],"prefix":"10.4103","volume":"13","author":[{"given":"Ahmad A.","family":"Algarni","sequence":"first","affiliation":[{"name":"Consultant Family Medicine, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad S.","family":"Alqarni","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanin A.","family":"Shalaby","sequence":"additional","affiliation":[{"name":"Clinical Research and Data Management, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nefroe.2018.05.004","article-title":"Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?","volume":"39","author":"Martinez Martinez-Castelao","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: A systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: Challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.kint.2016.11.023","article-title":"Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits","volume":"91","author":"Oellgaard","year":"2017","journal-title":"Kidney Int"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10557-017-6755-9","article-title":"Diabetic nephropathy: A tangled web to unweave","volume":"31","author":"Magee","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zoungas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of Liraglutide in type 2 diabetes and chronic kidney disease","volume":"15","author":"Mann","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-20240828","first-page":"311","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ckj\/sfac096","article-title":"Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice","volume":"15","author":"Aviles Bueno","year":"2022","journal-title":"Clin Kidney J"},{"key":"R17-20240828","first-page":"880","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: A post-hoc analysis of the SUSTAIN 1\u20137 randomised controlled trials","volume":"8","author":"Mann","year":"2020"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"3_Suppl","key":"R19-20240828","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/2047487317709554","article-title":"Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor","volume":"24","author":"Norhammar","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1031_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:25:42Z","timestamp":1787768742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1031_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1031_23","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}